Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals
The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applicati...
Gespeichert in:
Veröffentlicht in: | Journal of labelled compounds & radiopharmaceuticals 2018-03, Vol.61 (3), p.141-153 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 153 |
---|---|
container_issue | 3 |
container_start_page | 141 |
container_title | Journal of labelled compounds & radiopharmaceuticals |
container_volume | 61 |
creator | Notni, Johannes Wester, Hans‐Jürgen |
description | The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry.
The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. |
doi_str_mv | 10.1002/jlcr.3582 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1965261219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1965261219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</originalsourceid><addsrcrecordid>eNp1kc1O3DAUha2qCAbKoi-ALHVTFoHrn2Ti7qoRtKCRkEbTteWxb5gMSRzsRIhdH4Fn5EnwdIBFJVZXuuc7R1f3EPKVwRkD4OebxoYzkZf8E5kwUCpjQsrPZAKi4JksQRyQwxg3AEmTcp8ccMWkEEU5Ic0Cn_8-Deu6u6u7WzqskQbfIPUVDcbVvsXBNLSOfvA9xh906R9McJEaWo3DGJBa31nsB1r5sHUH0_k41Hbn7tcmtMbimDamiV_IXpUGHr_OI_Ln8mI5-53Nb35dzX7OMyvKkmdWcclgVSowAsHlRoqiEJVyFo11qEoHplTTqXGYwyrJhROMO5RGgCyqShyR77vcPvj7EeOg2zpabBrToR-jZqrIecE4Uwn99h-68WPo0nWaA1OQMyGmiTrdUTb4GANWug91a8KjZqC3FehtBXpbQWJPXhPHVYvunXz7eQLOd8BD3eDjx0n6ej5b_It8ARZmkx0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019051337</pqid></control><display><type>article</type><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Notni, Johannes ; Wester, Hans‐Jürgen</creator><creatorcontrib>Notni, Johannes ; Wester, Hans‐Jürgen</creatorcontrib><description>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry.
The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</description><identifier>ISSN: 0362-4803</identifier><identifier>EISSN: 1099-1344</identifier><identifier>DOI: 10.1002/jlcr.3582</identifier><identifier>PMID: 29143368</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Bismuth isotopes ; Data processing ; Diagnosis ; Diagnostic systems ; Dosimeters ; Dosimetry ; Humans ; Industrial engineering ; Isotopes ; Manufacturing engineering ; Metals, Heavy - chemistry ; molecular imaging ; molecular radiotherapy ; Nuclides ; Organometallic Compounds - chemistry ; positron emission tomography ; Precision medicine ; Production costs ; Radioisotopes ; Radioisotopes - chemistry ; radionuclides ; Radiopharmaceuticals - chemical synthesis ; Radiopharmaceuticals - chemistry ; Radiopharmaceuticals - therapeutic use ; Rare diseases ; Terbium ; Terbium isotopes ; Theranostic Nanomedicine - methods ; Tracers ; Zirconium isotopes</subject><ispartof>Journal of labelled compounds & radiopharmaceuticals, 2018-03, Vol.61 (3), p.141-153</ispartof><rights>Copyright © 2017 John Wiley & Sons, Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</citedby><cites>FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</cites><orcidid>0000-0002-3964-3391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjlcr.3582$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjlcr.3582$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29143368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Notni, Johannes</creatorcontrib><creatorcontrib>Wester, Hans‐Jürgen</creatorcontrib><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><title>Journal of labelled compounds & radiopharmaceuticals</title><addtitle>J Labelled Comp Radiopharm</addtitle><description>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry.
The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</description><subject>Animals</subject><subject>Bismuth isotopes</subject><subject>Data processing</subject><subject>Diagnosis</subject><subject>Diagnostic systems</subject><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>Humans</subject><subject>Industrial engineering</subject><subject>Isotopes</subject><subject>Manufacturing engineering</subject><subject>Metals, Heavy - chemistry</subject><subject>molecular imaging</subject><subject>molecular radiotherapy</subject><subject>Nuclides</subject><subject>Organometallic Compounds - chemistry</subject><subject>positron emission tomography</subject><subject>Precision medicine</subject><subject>Production costs</subject><subject>Radioisotopes</subject><subject>Radioisotopes - chemistry</subject><subject>radionuclides</subject><subject>Radiopharmaceuticals - chemical synthesis</subject><subject>Radiopharmaceuticals - chemistry</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Rare diseases</subject><subject>Terbium</subject><subject>Terbium isotopes</subject><subject>Theranostic Nanomedicine - methods</subject><subject>Tracers</subject><subject>Zirconium isotopes</subject><issn>0362-4803</issn><issn>1099-1344</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1O3DAUha2qCAbKoi-ALHVTFoHrn2Ti7qoRtKCRkEbTteWxb5gMSRzsRIhdH4Fn5EnwdIBFJVZXuuc7R1f3EPKVwRkD4OebxoYzkZf8E5kwUCpjQsrPZAKi4JksQRyQwxg3AEmTcp8ccMWkEEU5Ic0Cn_8-Deu6u6u7WzqskQbfIPUVDcbVvsXBNLSOfvA9xh906R9McJEaWo3DGJBa31nsB1r5sHUH0_k41Hbn7tcmtMbimDamiV_IXpUGHr_OI_Ln8mI5-53Nb35dzX7OMyvKkmdWcclgVSowAsHlRoqiEJVyFo11qEoHplTTqXGYwyrJhROMO5RGgCyqShyR77vcPvj7EeOg2zpabBrToR-jZqrIecE4Uwn99h-68WPo0nWaA1OQMyGmiTrdUTb4GANWug91a8KjZqC3FehtBXpbQWJPXhPHVYvunXz7eQLOd8BD3eDjx0n6ej5b_It8ARZmkx0</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Notni, Johannes</creator><creator>Wester, Hans‐Jürgen</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3964-3391</orcidid></search><sort><creationdate>201803</creationdate><title>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</title><author>Notni, Johannes ; Wester, Hans‐Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-c92410b890a3e0d5a43663f9dceacde98d0a8977ade50b5a46d312de4a3046ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Bismuth isotopes</topic><topic>Data processing</topic><topic>Diagnosis</topic><topic>Diagnostic systems</topic><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>Humans</topic><topic>Industrial engineering</topic><topic>Isotopes</topic><topic>Manufacturing engineering</topic><topic>Metals, Heavy - chemistry</topic><topic>molecular imaging</topic><topic>molecular radiotherapy</topic><topic>Nuclides</topic><topic>Organometallic Compounds - chemistry</topic><topic>positron emission tomography</topic><topic>Precision medicine</topic><topic>Production costs</topic><topic>Radioisotopes</topic><topic>Radioisotopes - chemistry</topic><topic>radionuclides</topic><topic>Radiopharmaceuticals - chemical synthesis</topic><topic>Radiopharmaceuticals - chemistry</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Rare diseases</topic><topic>Terbium</topic><topic>Terbium isotopes</topic><topic>Theranostic Nanomedicine - methods</topic><topic>Tracers</topic><topic>Zirconium isotopes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Notni, Johannes</creatorcontrib><creatorcontrib>Wester, Hans‐Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of labelled compounds & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Notni, Johannes</au><au>Wester, Hans‐Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals</atitle><jtitle>Journal of labelled compounds & radiopharmaceuticals</jtitle><addtitle>J Labelled Comp Radiopharm</addtitle><date>2018-03</date><risdate>2018</risdate><volume>61</volume><issue>3</issue><spage>141</spage><epage>153</epage><pages>141-153</pages><issn>0362-4803</issn><eissn>1099-1344</eissn><abstract>The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications. We furthermore discuss the different practical requirements for diagnostic and therapeutic radiopharmaceuticals and the resulting consequences for efficient development of clinically useful pairs of radionuclide theranostics, with particular emphasis on the underlying economical factors. Based on an exemplary assessment of overall production costs for 68Ga and 18F radiopharmaceuticals, we venture a look into the future of theranostics and predict that high‐throughput PET applications, that is, diagnosis of frequent conditions, will ultimately rely on 18F tracers. PET radiometals will occupy a niche in the clinical low‐throughput sector (diagnosis of rare diseases), but above all, dominate preclinical research and clinical translation. Matched isotope pairs will be of lesser relevance for theranostics but may become important for future PET‐based therapeutic dosimetry.
The potential and future role of certain metal radionuclides, for example, 44Sc, 89Zr, 86Y, 64Cu, 68Ga, 177Lu, 225Ac, and 213Bi, and several terbium isotopes has been controversially discussed in the past decades. Furthermore, the possible benefits of “matched pairs” of isotopes for tandem applications of diagnostics and therapeutics (theranostics) have been emphasized, while such approaches still have not made their way into routine clinical practice. Analysis of bibliographical data illustrates how popularity of certain nuclides has been promoted by cycles of availability and applications.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29143368</pmid><doi>10.1002/jlcr.3582</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3964-3391</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0362-4803 |
ispartof | Journal of labelled compounds & radiopharmaceuticals, 2018-03, Vol.61 (3), p.141-153 |
issn | 0362-4803 1099-1344 |
language | eng |
recordid | cdi_proquest_miscellaneous_1965261219 |
source | MEDLINE; Wiley Online Library Journals |
subjects | Animals Bismuth isotopes Data processing Diagnosis Diagnostic systems Dosimeters Dosimetry Humans Industrial engineering Isotopes Manufacturing engineering Metals, Heavy - chemistry molecular imaging molecular radiotherapy Nuclides Organometallic Compounds - chemistry positron emission tomography Precision medicine Production costs Radioisotopes Radioisotopes - chemistry radionuclides Radiopharmaceuticals - chemical synthesis Radiopharmaceuticals - chemistry Radiopharmaceuticals - therapeutic use Rare diseases Terbium Terbium isotopes Theranostic Nanomedicine - methods Tracers Zirconium isotopes |
title | Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re%E2%80%90thinking%20the%20role%20of%20radiometal%20isotopes:%20Towards%20a%20future%20concept%20for%20theranostic%20radiopharmaceuticals&rft.jtitle=Journal%20of%20labelled%20compounds%20&%20radiopharmaceuticals&rft.au=Notni,%20Johannes&rft.date=2018-03&rft.volume=61&rft.issue=3&rft.spage=141&rft.epage=153&rft.pages=141-153&rft.issn=0362-4803&rft.eissn=1099-1344&rft_id=info:doi/10.1002/jlcr.3582&rft_dat=%3Cproquest_cross%3E1965261219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019051337&rft_id=info:pmid/29143368&rfr_iscdi=true |